MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

The latest financial statement is for the quarter ending 2026-03-31.

Cash Flow Overview

Unit: Dollar
Positive Cash Flow Breakdown
    • Accounts payable and accrued lia...
    • Share-based compensation
    • Accounts and other receivable
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Effect of exchange rate changes ...
    • Payments for issuance costs of c...

Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Cash and cash equivalents at beginning of period
-10,792,172 1,037,320 -
Gain on loan forgiveness
--0 0
Net loss
-4,218,332 -2,247,669 -2,228,358 -4,957,165
Depreciation and amortization
25,872 25,460 25,868 93,405
Share-based compensation
484,853 399,862 404,425 325,217
Accounts and other receivable
-211,345 -217,387 359,828 18,159
Prepaid expenses and other current assets
-36,124 155,922 -34,477 -73,355
Accounts payable and accrued liabilities
1,443,516 -326,452 402,422 -1,117,921
Net cash used in operating activities
-2,016,622 -2,087,334 -1,720,994 -5,601,268
Repayment of debt
--0 0
Proceeds from issuance of common shares
0 3,497,825 220,501 7,497,133
Proceeds from issuance of series a-1 preferred shares and warrants
0 0 0 1,540,820
Proceeds from issuance of series b-1 preferred shares-Series B1Preferred Stock
0 -0 8,340,000
Payments for issuance costs of common shares-Common Stock And Warrants
8,980 142,406 34,018 294,935
Payments for issuance costs of common shares-Preferred Stock
0 -0 215,157
Payment for issuance costs of warrants
0 -0 23,446
Net cash provided by financing activities
-8,980 3,355,419 186,483 16,844,415
Effect of exchange rate changes on cash and cash equivalents
-22,463 -8,509 -35,007 81,223
Net change in cash and cash equivalents
-2,048,065 1,259,576 -1,569,518 11,324,370
Cash and cash equivalents, beginning of the period
12,051,748 ---
Cash and cash equivalents at end of period
-12,051,748 10,792,172 -
Cash and cash equivalents, end of the period
10,003,683 ---
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Net change in cashand cash...-$2,048,065 Accounts payable andaccrued liabilities$1,443,516 Share-based compensation$484,853 Accounts and otherreceivable-$211,345 Prepaid expenses andother current assets-$36,124 Depreciation andamortization$25,872 Net cash used inoperating activities-$2,016,622 Effect of exchange ratechanges on cash and cash...-$22,463 Net cash provided byfinancing activities-$8,980 Canceled cashflow$2,201,710 Net loss-$4,218,332 Payments for issuancecosts of common...$8,980

Edesa Biotech, Inc. (EDSA)

Edesa Biotech, Inc. (EDSA)